John Longshore: Nothing unites the oncology world quite like ASCO
, Driving scientific innovation in oncology diagnostics as the Head of Scientific Affairs for Global Oncology Diagnostics at AstraZeneca, shared on LinkedIn:
“There is no place I’d rather be in late spring than in Chicago for ASCO! Every year, this congress provides a space for cutting-edge science, readouts on the latest clinical studies, and time to connect with colleagues from around the globe.
It was amazing to see the continued evolution of personalized medicine and targeted therapies at ASCO2024 – we have come a long way from systemic therapies! The advancement of early detection and the movement of therapies into earlier stages is also promising, as these targeted approaches are essential in the fight against cancer.
Liquid biopsy technology continues to impress, with emerging data from multiple tumor types. It’s exciting to see this sample type, which will be required for monitoring, minimal residual disease and early detection, expand in utility across many solid tumor types.
The number of digital and computational pathology vendors and solutions is rapidly expanding. To drive adoption of this technology, we need data on its clinical value and impact on the efficiency of pathologists. The costs of adoption are high, but the benefits to both patients and pathologists will be tremendous.
Nothing unites the oncology world quite like ASCO. The connections made, the medical and scientific content shared, and the technological advancements demonstrated, all point to a brighter future in the fight against cancer.”
Source: John Longshore/LinkedIn
